glp-1 receptor agonists in pediatric and adolescent obesity Updates on Anti-Obesity Medications Children Adolescents Metabolic outcomes and safety of
Description
Osinski C, Le Glau L, Poitou C, de Toro-Martin J, Genser L, Fradet M, et al
Lixisenatide ( n = 1, ELIXA [13])
LEADER Trial Investigators
Gut 2009;58:990-7.ArticlePubMed 49
The researchers winnowed down the Reddit posts to more than 33,600 from nearly 14,600 unique users
Patients changing from a once-daily GLP-1 receptor agonist because of GI adverse effects may be better suited to a once-weekly medication with adjustable doses so they can start at a lower dose increment, given that GI adverse effects are often dose-dependent
